CD274 and neoplasm: Across all approaches, the most tremendous success with immune checkpoint inhibition is anticipated in biomarker-driven settings, particularly in patients whose tumors are MSI-H/dMMR, have high PD-L1 expression, CDK12 mutations, or elevated tumor mutational burden [121].